The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics

Trends Immunol. 2020 Nov;41(11):965-967. doi: 10.1016/j.it.2020.09.008. Epub 2020 Sep 23.

Abstract

The current pandemic of coronavirus disease (COVID-19) caused by SARS-CoV-2 is a significant global health challenge. A recent study by Carvelli and colleagues now demonstrates the involvement of complement C5a and its receptor C5aR1 in disease progression and suggests that blockade of the C5a-C5aR1 axis may represent a potential therapeutic strategy against COVID-19.

Keywords: COVID-19; GPCRs; SARS-CoV-2; cellular signaling; complement system; drug discovery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / pharmacology
  • Betacoronavirus / drug effects
  • Betacoronavirus / immunology*
  • Betacoronavirus / physiology
  • COVID-19
  • Complement C5a / immunology*
  • Complement C5a / metabolism
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / therapy
  • Coronavirus Infections / virology
  • Disease Models, Animal
  • Humans
  • Pandemics
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / therapy
  • Pneumonia, Viral / virology
  • Receptor, Anaphylatoxin C5a / immunology*
  • Receptor, Anaphylatoxin C5a / metabolism
  • Receptors, G-Protein-Coupled / immunology
  • Receptors, G-Protein-Coupled / metabolism
  • SARS-CoV-2
  • Signal Transduction / drug effects
  • Signal Transduction / immunology

Substances

  • Antibodies, Monoclonal
  • C5AR1 protein, human
  • Receptor, Anaphylatoxin C5a
  • Receptors, G-Protein-Coupled
  • Complement C5a